Crossmark

Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis

Crossref DOI link: https://doi.org/10.1038/s41391-018-0055-8

Published Online: 2018-06-06

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tan, Pui San

Aguiar, Pedro Jr.

Haaland, Benjamin

Lopes, Gilberto
License Information

Text and Data Mining valid from 2018-06-06
More Information

Article History

Received: 10 January 2018

Revised: 15 March 2018

Accepted: 21 March 2018

First Online: 6 June 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below